Ark Biosciences is a technology company.
Ark Biosciences has raised $40.0M across 2 funding rounds.
Ark Biosciences has raised $40.0M in total across 2 funding rounds.
Ark Biosciences is a clinical-stage global biopharmaceutical company specializing in developing innovative medicines primarily for respiratory viral infections, pediatric diseases, and pulmonary conditions such as idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD). Its product portfolio includes antiviral drugs like ziresovir (AK0529), the first direct-acting RSV antiviral with positive phase III results, and AK0901, an FDA-approved ADHD treatment for children. The company serves the healthcare industry worldwide, focusing on unmet medical needs by providing safer, more effective therapies. Ark Biosciences has demonstrated strong growth momentum with successful clinical trials, including positive Phase II results for its anti-fibrotic candidate AK3280 and ongoing preparations for pivotal Phase III studies[1][4].
Founded in 2014 and headquartered in Shanghai, China, Ark Biosciences was established by a team of professionals with expertise in biotechnology and pharmaceutical R&D. The company emerged from a vision to address critical respiratory and pediatric diseases through innovative drug development. Early traction came from its strategic collaborations with multinational pharmaceutical companies such as Roche and Genentech, as well as academic institutions like the Scripps Research Institute. These partnerships, combined with in-house R&D capabilities, helped Ark Biosciences build a differentiated pipeline and achieve key clinical milestones, including the global first successful phase III trial of an anti-RSV drug[1][2].
Ark Biosciences rides the global trend of precision biopharmaceutical innovation focused on respiratory and pediatric diseases, areas with significant unmet medical needs and growing patient populations. The timing is critical due to increasing awareness of respiratory infections like RSV and chronic pulmonary diseases, alongside a demand for safer pediatric medications. Market forces such as aging populations, rising chronic disease prevalence, and regulatory support for innovative therapies favor Ark’s growth. By advancing novel antiviral and anti-fibrotic drugs, Ark Biosciences influences the biotech ecosystem by setting new standards for treatment efficacy and safety, fostering collaborations that accelerate drug discovery and development globally[1][4].
Ark Biosciences is poised for significant expansion as it moves key candidates like AK3280 into pivotal Phase III trials and continues to commercialize approved products such as AK0901 for ADHD. Future trends shaping its journey include advances in molecular biology, personalized medicine, and increasing global investment in respiratory and pediatric therapeutics. The company’s influence is likely to grow as it delivers new treatment options that improve patient outcomes and addresses large, underserved markets. Continued strategic partnerships and clinical successes will be critical to sustaining momentum and expanding its global footprint in biopharmaceutical innovation[1][4].
Ark Biosciences has raised $40.0M in total across 2 funding rounds.
Ark Biosciences's investors include Qiming Venture Partners.
Ark Biosciences has raised $40.0M across 2 funding rounds. Most recently, it raised $32.0M Series B in May 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2018 | $32.0M Series B | Qiming Venture Partners | |
| Feb 1, 2017 | $8.0M Series A | Qiming Venture Partners |